|Videos|June 15, 2017

How Does Photodynamic Therapy Work?

Caetano P. Sabino, BSc, PhD Student, explains how photodynamic therapy works.

Caetano P. Sabino, BSc, PhD Student, Clinical Analysis, School of Pharmaceutical Sciences, University of Sao Paulo, explains how photodynamic therapy works.

Interview Transcript (slightly modified for readability)

“Photodynamic therapy works pretty much in a similar way as photosynthesis, for example, where plants use pigments—chlorophyll—to absorb sunlight in specific wavelengths. So, there’s blue light, and there’s red light, and it shines back the green light, that we see. The plants use it to donate electrons, [and] to produce glucose; so, this is a chemical reaction that is induced after light absorption. What we do is use other pigments, or dyes, or photoactive drugs that we term as photosensitizers, to absorb light at specific wavelengths, so we have a molecular targeting principle, to produce high yields of reactive oxygen species, and they will be produced only in the region where the photosensitive drug is. So, it’s going to be retained to the bacteria where it was selectively incorporated.”


Related to this article

How The Food Safety Surveillance Infrastructure Works in the US
In the first episode of our news series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates, and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
This Week's Top 5 Infectious Disease News Stories: September 12-September 18, 2026
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
Ceftriaxone Safety: Separating Signal From Risk
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.
Treatment of Latent Tuberculosis in a Trice
A retrospective study of 225 patients across Cook County Department of Health clinics found that the novel 1-month 1HP regimen (isoniazid plus rifapentine) for latent TB infection had a completion rate comparable to standard longer regimens and was well tolerated, suggesting it may be a viable shorter alternative.